BrainsWay Valuation Multiples

Discover BrainsWay's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Nanosonics, Delcath Systems, Cytek Biosciences, OrthoPediatrics and more.

BrainsWay Overview

About BrainsWay

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.


Founded

2006

HQ

Israel

Employees

120

Financials (LTM)

Revenue: $64M
EBITDA: $11M

EV

$522M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

BrainsWay Financials

BrainsWay reported last 12-month revenue of $64M and EBITDA of $11M.

In the same LTM period, BrainsWay generated $48M in gross profit, $11M in EBITDA, and $11M in net income.

Revenue (LTM)


BrainsWay P&L

In the most recent fiscal year, BrainsWay reported revenue of $52M and EBITDA of $7M.

BrainsWay is profitable as of last fiscal year, with gross margin of 75%, EBITDA margin of 13%, and net margin of 15%.

See analyst estimates for BrainsWay
LTMLast FY202320242025202620272028
Revenue$64M$52M$32M$41M$52M
Gross Profit$48M$39M$23M$31M$39M
Gross Margin75%75%74%75%75%
EBITDA$11M$7M($3M)$5M$7M
EBITDA Margin18%13%(8%)13%13%
EBIT Margin13%8%(16%)3%8%
Net Profit$11M$8M($4M)$3M$8M
Net Margin17%15%(13%)7%15%
Net Debt-($61M)---

Financial data powered by Morningstar, Inc.

BrainsWay Stock Performance

BrainsWay has current market cap of $578M, and enterprise value of $522M.

Market Cap Evolution


BrainsWay's stock price is $14.38.

BrainsWay share price decreased by 4.3% in the last 30 days, and by 5.8% in the last year.

BrainsWay has an EPS (earnings per share) of $0.19.

See more trading valuation data for BrainsWay
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$522M$578M-4.3%-4.3%-6.7%-5.8%$0.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

BrainsWay Valuation Multiples

BrainsWay trades at 8.2x EV/Revenue multiple, and 45.7x EV/EBITDA.

See NTM and 2027E valuation multiples for BrainsWay

EV / Revenue (LTM)


BrainsWay Financial Valuation Multiples

As of September 2, 2026, BrainsWay has market cap of $578M and EV of $522M.

BrainsWay has a P/E ratio of 53.4x.

LTMLast FY202320242025202620272028
EV/Revenue8.2x10.0x16.4x12.7x10.0x
EV/EBITDA45.7x76.7x(204.0x)97.5x76.7x
EV/EBIT61.2x120.8x(105.3x)n/m120.8x
EV/Gross Profit10.9x13.3x22.3x17.1x13.3x
P/E53.4x76.3x(137.8x)197.9x76.3x
EV/FCF-34.5xn/m80.3x34.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified BrainsWay Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

BrainsWay Margins & Growth Rates

BrainsWay grew revenue by 32% and EBITDA by 99% in the last fiscal year.

In the most recent fiscal year, BrainsWay reported gross margin of 75%, EBITDA margin of 13%, and net margin of 15%.

See estimated margins and future growth rates for BrainsWay

BrainsWay Margins

Last FY202420252026202720282029
Gross Margin75%75%75%75%
EBITDA Margin13%13%13%20%
EBIT Margin8%3%8%15%
Net Margin15%7%15%18%
FCF Margin29%16%29%-

BrainsWay Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth32%29%27%32%
Gross Profit Growth32%30%29%32%
EBITDA Growth99%(309%)27%99%
EBIT Growth145%(128%)211%145%
Net Profit Growth63%(170%)159%63%
FCF Growth-(690%)133%-

Data powered by FactSet, Inc. and Morningstar, Inc.

BrainsWay Operational KPIs

BrainsWay's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.

BrainsWay's Rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BrainsWay's Rule of X is 101% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for BrainsWay
LTMLast FY202320242025202620272028
Rule of 4044%52%---
Bessemer Rule of X82%101%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue32%15%19%17%15%
G&A Expenses to Revenue12%0%49%35%0%
R&D Expenses to Revenue18%18%21%18%18%
Opex to Revenue-67%89%71%67%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

BrainsWay Competitors

BrainsWay competitors include Nanosonics, Delcath Systems, Cytek Biosciences, OrthoPediatrics, Revenio Group, SD Biosensor, IBA Group, Cerus, Ocumension and Lumibird.

Most BrainsWay public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Nanosonics3.3x3.3x27.3x28.5x
Delcath Systems5.6x4.8x506.5x27.8x
Cytek Biosciences1.8x1.8x(15.2x)(68.1x)
OrthoPediatrics2.8x2.5x(54.2x)30.3x
Revenio Group4.2x2.6x16.7x12.0x
SD Biosensor0.8x-(0.8x)-
IBA Group0.9x0.9x15.4x10.9x
Cerus2.7x2.2x(111.0x)42.1x

This data is available for Pro users. Sign up to see all BrainsWay competitors and their valuation data.

Start Free Trial

Investments by BrainsWay

BrainsWay has invested in 7 companies to date.

Latest investment by BrainsWay was on July 15th 2026. BrainsWay invested in Sound Minds Behavioral in their $500K Strategic investment round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by BrainsWay

Sound Minds Behavioral
Hopemark Health
Neurolief
Brainstim Health
Description
Sound Minds Behavioral is a behavioral health provider that creates supportive settings for mental and emotional recovery.
Hopemark Health is a psychiatric clinic that offers mental health care, ketamine therapy, and genetic testing services.
Neurolief is an Israel-headquartered neuromodulation company treating mental health and neurological disorders with non-invasive devices. Its platform delivers multi-channel electrical stimulation to key cranial neural pathways simultaneously, modulating brain areas for mood regulation and pain relief. Targeting depression, anxiety, and migraines, the wearable system offers home-based therapy sessions. Neurolief employs neuroscience veterans to refine pulse patterns based on clinical feedback from European and US trials.
BrainStim Health manages clinics delivering neuroplasticity treatments including TMS and ketamine for mental health conditions.
HQ CountryUnited StatesUnited StatesIsraelCanada
HQ City
Baltimore, MD
Oak Brook, IL
Netanya
-
Deal Date15 Jul 202617 May 202625 Mar 202619 Feb 2026
RoundStrategic investmentStrategic investmentUndisclosed stageStrategic investment
Raised$500K$2M$6M$1M
InvestorsBrainsWayBrainsWayBrainsWayBrainsWay
Valuationundisclosed$3Mundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all BrainsWay investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About BrainsWay

When was BrainsWay founded?BrainsWay was founded in 2006.
Where is BrainsWay headquartered?BrainsWay is headquartered in Israel.
How many employees does BrainsWay have?As of today, BrainsWay has over 120 employees.
Who is the CEO of BrainsWay?BrainsWay's CEO is Hadar Levy.
Is BrainsWay publicly listed?Yes, BrainsWay is a public company listed on Tel Aviv Stock Exchange.
What is the stock symbol of BrainsWay?BrainsWay trades under BWAY ticker.
When did BrainsWay go public?BrainsWay went public in 2019.
Who are competitors of BrainsWay?BrainsWay main competitors include Nanosonics, Delcath Systems, Cytek Biosciences, OrthoPediatrics, Revenio Group, SD Biosensor, IBA Group, Cerus, Ocumension, Lumibird.
What is the current market cap of BrainsWay?BrainsWay's current market cap is $578M.
What is the current revenue of BrainsWay?BrainsWay's last 12 months revenue is $64M.
What is the current revenue growth of BrainsWay?BrainsWay revenue growth (NTM/LTM) is 26%.
What is the current EV/Revenue multiple of BrainsWay?Current revenue multiple of BrainsWay is 8.2x.
What is the current EBITDA of BrainsWay?BrainsWay's last 12 months EBITDA is $11M.
What is BrainsWay's EBITDA margin?BrainsWay's last 12 months EBITDA margin is 18%.
What is the current EV/EBITDA multiple of BrainsWay?Current EBITDA multiple of BrainsWay is 45.7x.
How many companies BrainsWay has acquired to date?BrainsWay hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies BrainsWay has invested to date?As of September 2026, BrainsWay has invested in 7 companies.
What was the last BrainsWay investment?On 15th July 2026 BrainsWay invested in Sound Minds Behavioral, participating in a $500K Strategic investment round.
In what companies BrainsWay invested in?BrainsWay invested in Neurolief, Stella Mental Health, Axis Integrated Mental Health, Hopemark Health, Heading Health, Brainstim Health, and Sound Minds Behavioral.

See public comps similar to BrainsWay

Lists including BrainsWay

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial